AMPH
Income statement / Annual
Last year (2025), Amphastar Pharmaceuticals Inc's total revenue was $719.89 M,
a decrease of 1.65% from the previous year.
In 2025, Amphastar Pharmaceuticals Inc's net income was $98.09 M.
See Amphastar Pharmaceuticals Inc,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2025
|
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
| Period Ended |
12/31/2025 |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
| Operating Revenue |
$719.89 M |
$731.97 M |
$644.40 M |
$498.99 M |
$437.77 M |
$349.85 M |
$322.36 M |
$294.67 M |
$240.18 M |
$255.17 M |
| Cost of Revenue |
$363.83 M
|
$358.11 M
|
$293.27 M
|
$250.13 M
|
$238.03 M
|
$206.51 M
|
$190.43 M
|
$187.68 M
|
$149.38 M
|
$150.98 M
|
| Gross Profit |
$356.06 M
|
$373.86 M
|
$351.12 M
|
$248.86 M
|
$199.74 M
|
$143.34 M
|
$131.92 M
|
$106.99 M
|
$90.80 M
|
$104.19 M
|
| Gross Profit Ratio |
0.49
|
0.51
|
0.54
|
0.5
|
0.46
|
0.41
|
0.41
|
0.36
|
0.38
|
0.41
|
| Research and Development Expenses |
$85.84 M
|
$73.91 M
|
$73.74 M
|
$74.77 M
|
$60.93 M
|
$67.23 M
|
$68.85 M
|
$57.56 M
|
$43.42 M
|
$41.20 M
|
| General & Administrative Expenses |
$85.93 M
|
$56.72 M
|
$51.54 M
|
$45.06 M
|
$51.43 M
|
$50.38 M
|
$50.28 M
|
$49.89 M
|
$44.46 M
|
$41.83 M
|
| Selling & Marketing Expenses |
$43.89 M
|
$37.80 M
|
$28.85 M
|
$21.53 M
|
$17.49 M
|
$14.78 M
|
$12.83 M
|
$8.16 M
|
$6.46 M
|
$5.47 M
|
| Selling, General & Administrative Expenses |
$129.81 M
|
$94.52 M
|
$80.39 M
|
$66.59 M
|
$68.92 M
|
$65.16 M
|
$63.11 M
|
$58.04 M
|
$50.92 M
|
$47.30 M
|
| Other Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
-$746.00 K
|
| Operating Expenses |
$215.65 M
|
$168.44 M
|
$154.13 M
|
$141.36 M
|
$129.85 M
|
$132.39 M
|
$131.96 M
|
$115.61 M
|
$94.33 M
|
$88.50 M
|
| Cost And Expenses |
$579.48 M
|
$526.55 M
|
$447.41 M
|
$391.49 M
|
$367.88 M
|
$338.89 M
|
$322.40 M
|
$303.29 M
|
$243.71 M
|
$239.47 M
|
| Interest Income |
$8.68 M
|
$10.61 M
|
$5.46 M
|
$1.32 M
|
$601.00 K
|
$642.00 K
|
$997.00 K
|
$456.00 K
|
$425.00 K
|
$270.00 K
|
| Interest Expense |
$25.48 M
|
$30.34 M
|
$27.16 M
|
$1.85 M
|
$885.00 K
|
$374.00 K
|
$119.00 K
|
$243.00 K
|
$826.00 K
|
$1.02 M
|
| Depreciation & Amortization |
$0.00
|
$57.21 M
|
$41.78 M
|
$28.28 M
|
$26.53 M
|
$25.18 M
|
$21.12 M
|
$16.52 M
|
$15.81 M
|
$14.56 M
|
| EBITDA |
$149.11 M |
$277.31 M |
$240.29 M |
$146.16 M |
$111.56 M |
$30.19 M |
$81.47 M |
$6.83 M |
$11.90 M |
$30.53 M |
| EBITDA Ratio |
0.21
|
0.38
|
0.37
|
0.29
|
0.25
|
0.09
|
0.25
|
0.02
|
0.05
|
0.12
|
| Operating Income Ratio |
0.2
|
0.28
|
0.31
|
0.22
|
0.16
|
0.03
|
-0
|
-0.03
|
-0
|
0.06
|
| Total Other Income/Expenses Net |
-$16.78 M
|
-$16.23 M
|
-$27.61 M
|
$7.37 M
|
$14.04 M
|
-$6.32 M
|
$60.27 M
|
-$1.30 M
|
$2.52 M
|
-$746.00 K
|
| Income Before Tax |
$123.62 M
|
$189.19 M
|
$169.38 M
|
$114.86 M
|
$83.93 M
|
$4.64 M
|
$60.23 M
|
-$9.93 M
|
$1.62 M
|
$14.95 M
|
| Income Before Tax Ratio |
0.17
|
0.26
|
0.26
|
0.23
|
0.19
|
0.01
|
0.19
|
-0.03
|
0.01
|
0.06
|
| Income Tax Expense |
$25.53 M
|
$29.67 M
|
$31.83 M
|
$23.48 M
|
$20.63 M
|
$3.54 M
|
$13.72 M
|
-$3.27 M
|
-$2.89 M
|
$4.41 M
|
| Net Income |
$98.09 M
|
$159.52 M
|
$137.55 M
|
$91.39 M
|
$62.12 M
|
$1.40 M
|
$48.94 M
|
-$5.74 M
|
$4.51 M
|
$10.53 M
|
| Net Income Ratio |
0.14
|
0.22
|
0.21
|
0.18
|
0.14
|
0
|
0.15
|
-0.02
|
0.02
|
0.04
|
| EPS |
2.1 |
3.29 |
2.85 |
1.88 |
1.3 |
0.0298 |
1.04 |
-0.12 |
0.1 |
0.23 |
| EPS Diluted |
2.03 |
3.06 |
2.6 |
1.74 |
1.25 |
0.0286 |
0.98 |
-0.12 |
0.09 |
0.22 |
| Weighted Average Shares Out |
$46.74 M
|
$48.43 M
|
$48.27 M
|
$48.55 M
|
$47.78 M
|
$47.04 M
|
$46.98 M
|
$46.40 M
|
$46.11 M
|
$45.38 M
|
| Weighted Average Shares Out Diluted |
$48.22 M
|
$52.06 M
|
$53.00 M
|
$52.43 M
|
$49.78 M
|
$49.12 M
|
$49.91 M
|
$46.40 M
|
$48.37 M
|
$47.50 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
